SKB BIO-B (06990): SKB103 new drug clinical trial application approved by the National Medical Products Administration.

SKB BIO-B(06990) announced that the new drug clinical trial application (IND) for SKB103, a bispecific antibody-drug conjugate (bsADC) targeting tumor-associated antigens and immunooncology tumor antigens (TAA-PD-L1), developed independently by the company, has been approved by the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for the treatment of advanced solid tumors. This is the company's first TAA-PD-L1 bsADC to enter the clinical stage, and the second bsADC for cancer treatment to enter the clinical stage after SKB571. As a leading company in the field of ADC, the company has established a strong leading advantage. Currently, the company's independently developed TROP2 ADC and HER2 ADC targeting human epithelial growth factor receptor 2 (HER2) have been approved for marketing and have shown significant clinical efficacy and differentiated competitive advantages. At the same time, the company is focusing on the iterative upgrade of cancer treatment, continuously expanding innovative layouts, building a diversified pipeline matrix covering radioconjugate drugs (RDC), bsADC, and other cutting-edge therapies, and making efforts to promote breakthroughs and innovations in the existing cancer treatment models.